Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population
- PMID: 17201138
Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population
Abstract
Background: 5,10-Methylenetetrahydrofolate reductase (MTHFR), a key enzyme in folate metabolism, plays a major role in the provision of methyl groups for DNA methylation; thymidylate synthase (TS) is a rate-limiting enzyme in the synthesis of dTMP and DNA repair. The clinical role of genetic polymorphisms of MTHFR and that of the TS enhancer region (TSER) were demonstrated in several clinical studies with colorectal, esophageal, gastric and breast cancer. However, there have never been any studies on the association between cholangiocarcinoma (CCC) and genetic polymorphisms of MTHFR and TSER. Therefore, the polymorphism of MTHFR and TSER, which share a common substrate, 5,10-methylenetetrahydrofolate, in CCC was examined, concurrently. The influence of these polymorphisms on plasma homocysteine levels was also investigated.
Patients and methods: Blood samples were obtained from 47 patients with CCC and 204 healthy control donors. Using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP), the C to T transition at position 677 of MTHFR and tandem repeat of 28bp in the enhancer region of TS gene were analyzed. Plasma homocysteine levels were also determined.
Results: According to the logistic regression model, a combination of MTHFR 677CC with the TSER 2R(+) genotype had a relative risk of 5.38 (95% CI, 1.23-23.56) of developing CCC compared to MTHFR 677CC with TSER 2R(-) (p = 0.0257). The level of homocysteine was lower in CCC patients than healthy controls without statistical significance (8.27 +/- 4.17 vs. 9.40 +/- 2.57, p = 0.093).
Conclusion: Our data suggest a role of MTHFR 677CC with the TSER 2R(+) genotype in increasing the risk of CCC. This study is the first to suggest an association between CCC and the polymorphisms of MTHFR and TSER.
Similar articles
-
Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion.Thromb Res. 2006;117(6):653-8. doi: 10.1016/j.thromres.2005.05.025. Epub 2005 Jun 27. Thromb Res. 2006. PMID: 15985285
-
Association of methylenetetrahydrofolate reductase (MTHFR 677C>T) and thymidylate synthase (TSER and TS 1494del6) polymorphisms with premature ovarian failure in Korean women.Menopause. 2012 Nov;19(11):1260-6. doi: 10.1097/gme.0b013e3182556b08. Menopause. 2012. PMID: 22713864
-
Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population.Anticancer Res. 2005 May-Jun;25(3B):2249-52. Anticancer Res. 2005. PMID: 16158971
-
5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: a new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease.Nutr Rev. 2005 Nov;63(11):398-407. doi: 10.1111/j.1753-4887.2005.tb00377.x. Nutr Rev. 2005. PMID: 16370225 Review.
-
Genetic polymorphism of drug metabolizing enzymes in association with risk of bile duct cancer.Asian Pac J Cancer Prev. 2012;13 Suppl:7-15. Asian Pac J Cancer Prev. 2012. PMID: 23480767 Review.
Cited by
-
A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.Mol Biol Rep. 2013 Jan;40(1):625-37. doi: 10.1007/s11033-012-2101-2. Epub 2012 Oct 19. Mol Biol Rep. 2013. PMID: 23076526 Review.
-
The Role of Single-Nucleotide Polymorphisms in Cholangiocarcinoma: A Systematic Review.Cancers (Basel). 2022 Dec 2;14(23):5969. doi: 10.3390/cancers14235969. Cancers (Basel). 2022. PMID: 36497451 Free PMC article. Review.
-
The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and tumor risk: evidence from 134 case-control studies.Mol Biol Rep. 2014 Jul;41(7):4659-73. doi: 10.1007/s11033-014-3337-9. Epub 2014 Apr 18. Mol Biol Rep. 2014. PMID: 24744129
-
JAK2V617F mutation in patients with portal vein thrombosis.Dig Dis Sci. 2008 Oct;53(10):2778-83. doi: 10.1007/s10620-008-0225-y. Epub 2008 Mar 15. Dig Dis Sci. 2008. PMID: 18343999
-
The Constellation of Risk Factors and Paraneoplastic Syndromes in Cholangiocarcinoma: Integrating the Endocrine Panel Amid Tumour-Related Biology (A Narrative Review).Biology (Basel). 2024 Aug 26;13(9):662. doi: 10.3390/biology13090662. Biology (Basel). 2024. PMID: 39336089 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical